Acerus Pharmaceuticals (OTCMKTS:ASPCF – Get Free Report) and Perrigo (NYSE:PRGO – Get Free Report) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, profitability, earnings, analyst recommendations and risk.
Valuation and Earnings
This table compares Acerus Pharmaceuticals and Perrigo”s revenue, earnings per share (EPS) and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Acerus Pharmaceuticals | $2.12 million | 0.80 | -$33.82 million | ($3.57) | -0.06 |
Perrigo | $4.66 billion | 0.73 | -$12.70 million | ($0.07) | -353.57 |
Perrigo has higher revenue and earnings than Acerus Pharmaceuticals. Perrigo is trading at a lower price-to-earnings ratio than Acerus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
Profitability
This table compares Acerus Pharmaceuticals and Perrigo’s net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Acerus Pharmaceuticals | -924.33% | N/A | -74.62% |
Perrigo | -2.81% | 6.79% | 2.99% |
Analyst Recommendations
This is a summary of recent recommendations for Acerus Pharmaceuticals and Perrigo, as provided by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Acerus Pharmaceuticals | 0 | 0 | 0 | 0 | N/A |
Perrigo | 0 | 1 | 3 | 0 | 2.75 |
Perrigo has a consensus price target of $37.00, indicating a potential upside of 49.49%. Given Perrigo’s higher probable upside, analysts plainly believe Perrigo is more favorable than Acerus Pharmaceuticals.
Volatility and Risk
Acerus Pharmaceuticals has a beta of 0.69, indicating that its share price is 31% less volatile than the S&P 500. Comparatively, Perrigo has a beta of 0.49, indicating that its share price is 51% less volatile than the S&P 500.
Summary
Perrigo beats Acerus Pharmaceuticals on 10 of the 13 factors compared between the two stocks.
About Acerus Pharmaceuticals
Acerus Pharmaceuticals Corp. is a pharmaceutical company. The firm is focused on the commercialization and development of prescription products that improve patient experience, with a focus in the field of men’s health. It focuses on therapeutics for urology, andrology, and endocrinology. Its products include Estrace and Natesto. The company was founded by Bruce D. Brydon, Rolf K. Reininghaus and Mark L. Thompson on September 9, 2008 and is headquartered in Mississauga, Canada.
About Perrigo
Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. It also offers healthy lifestyle products, such as smoking cessation, well-being, and weight management products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women's health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; rare diseases business; and other miscellaneous self-care products. The company sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, Compeed Stops, XLS, Arterin, Davitamon, Apiserum, Abtei, and Nicorette brands. It also offers contract manufacturing services. The company sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.
Receive News & Ratings for Acerus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acerus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.